GSK 2256294

Drug Profile

GSK 2256294

Alternative Names: GSK-2256294

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics
  • Mechanism of Action Epoxide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 13 May 2016 Efficacy and safety data from a phase I trial in Chronic obstructive pulmonary disease (In volunteers) presented at the Conference of the American Thoracic Society (ATS-2016) (NCT02262689)
  • 01 Apr 2015 GlaxoSmithKline completes a phase I trial in Healthy volunteers in USA (NCT02262689)
  • 01 Jan 2015 GlaxoSmithKline initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02262689)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top